Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

What COVID-19 vaccine and drug makers have to say about Omicron

12/02/2021 | 12:29pm EST

Dec 8 (Reuters) - The Omicron variant of the coronavirus has sparked fears that existing COVID-19 vaccines and treatment could be less effective against it.

South Africa's National Institute for Communicable Diseases said early epidemiological data suggested Omicron was able to evade some immunity, but existing vaccines should still protect against severe disease and death.

Here's what companies that make COVID-19 vaccines and drugs have said:

MODERNA

CEO Stéphane Bancel has warned that COVID-19 vaccines are unlikely to be as effective against the Omicron variant.

The company has said a new vaccine tailored for Omicron should be available as soon as March.

PFIZER-BIONTECH

Companies said a three-shot course of their COVID-19 vaccine was shown to generate a neutralizing effect against the new Omicron variant in a lab test.

Two vaccine doses resulted in significantly lower neutralising antibodies but a third dose increased the neutralising antibodies by a factor of 25, they said, adding that they can deliver an Omicron-based vaccine in March 2022.

Earlier, a lab study conducted in South Africa showed that Omicron variant can partially evade protection from two doses of the PFE/BNTX shot.

JOHNSON & JOHNSON

J&J said https://www.jnj.com/johnson-johnson-to-evaluate-its-covid-19-vaccine-against-new-omicron-covid-19-variant it was testing blood serum from participants in various trials to look for neutralizing activity against the Omicron variant. It was also pursuing an Omicron-specific vaccine and would progress it as needed.

The company, however, remains confident in the immune responses generated by its shot against other variants to date in clinical studies, said Mathai Mammen, global head of J&J arm Janssen Research & Development.

ASTRAZENECA PLC-UNIVERSITY OF OXFORD

AstraZeneca said it was examining the impact of Omicron on its vaccine, which is developed with Oxford University, and its antibody cocktail, adding it was hopeful its combination drug would retain efficacy.

REGENERON PHARMACEUTICALS INC

Its COVID-19 antibody drug could be less effective against Omicron, Regeneron said.

Based on its study of Omicron's individual mutations, "there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity", Regeneron said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.

ELI LILLY AND CO

The company, which also makes monoclonal antibody treatment, is working to understand the neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.

MERCK & Co Inc

Merck's experimental COVID-19 drug, molnupiravir, which it is co-developing with Ridgeback Biotherapeutics, should have similar activity against any new coronavirus variant, a company executive said.

NOVAVAX INC

May begin commercial manufacturing of a COVID-19 vaccine tailored for the Omicron coronavirus variant in January next year, while it tests whether or not its current vaccine works against the variant.

GILEAD SCIENCES INC

Gilead has said it believes its drug - Veklury or remdesivir - will continue to be active against the Omicron variant. It plans to conduct laboratory tests to confirm its analysis.

GSK-VIR BIOTECH

Laboratory analysis of the COVID-19 antibody therapy GlaxoSmithKline is developing with U.S. partner Vir Biotechnology has indicated the drug is effective against the new Omicron variant, the British drugmaker said. (Compilation by Manas Mishra, Oishee Majumdar and Leroy Leo and Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.76% 8769 Delayed Quote.1.82%
GILEAD SCIENCES, INC. 0.94% 67.87 Delayed Quote.-7.35%
GLAXOSMITHKLINE PLC -1.23% 1660.4 Delayed Quote.4.63%
MODERNA, INC. 3.76% 154.29 Delayed Quote.-41.48%
NOVAVAX, INC. 7.72% 78.4261 Delayed Quote.-49.03%
REGENERON PHARMACEUTICALS 1.01% 615.04 Delayed Quote.-4.16%
VIR BIOTECHNOLOGY, INC. 3.68% 32.32 Delayed Quote.-25.34%
Latest news "Economy & Forex"
02:29pCollapsed Pittsburgh bridge is one of 44,000 in poor condition in U.S
RE
02:28pIn letter to gulf states, lebanese gov't says lebanon "will not…
RE
02:25pAnalysis-Argentina traders cheer IMF breakthrough, caution long road ahead
RE
02:23pArgentina strikes breakthrough deal with IMF in $45 billion debt talks
RE
02:21pBritish police say have received information on Downing Street gatherings
RE
02:21pU.s. stocks pare gains, dow turns negative…
RE
02:20pBiden visits Pittsburgh bridge collapse site on trip to tout infrastructure funding
RE
02:18pWhy U.S. natural gas prices spiked by a record 70% on Thursday
RE
02:10pFED'S MATCHMAKER FEAR : Flatlining economy meets higher interest rates
RE
02:10pChevron kicks off oil industry's Q4 results with a miss
RE
Latest news "Economy & Forex"